He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Subscribe To Our Newsletter & Stay Updated
